# RDEA3170 PK/PD Study

> **NCT02608710** · PHASE1 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Gout

## Interventions

- **DRUG:** RDEA3170 4.5 mg
- **DRUG:** RDEA3170 6 mg
- **DRUG:** RDEA3170 12 mg

## Key facts

- **NCT ID:** NCT02608710
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2015-12
- **Final completion:** 2016-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608710, "RDEA3170 PK/PD Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02608710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*